Incepta, a leading Pharmaceutical manufacturer in Bangladesh, continues its voyage towards inherent dream to become a key contributor in the world Pharmaceutical market by maintaining a constant commitment to research, developing innovative products and quality management. Our unwavering determination to achieve excellence leads us to new global benchmarks.
Incepta is guided by its export mission to improve the health and well-being of people worldwide. Its corporate philosophy is to create new value around health-related products through science and advanced technology.
Incepta has always given very high priority to its Research and Development activities. This focus enabled Incepta to develop and market 124 generics for the first time ever in Bangladesh pharmaceutical market. The company has successfully developed 639 dosage forms of 335 generics in different specialties that are currently selling in the local as well as international market.
Incepta is continuing to introduce new and technologically advanced molecules and innovative dosage forms. These molecules and dosage forms have played key role towards the rapid growth of the company in the last eleven years. Currently Incepta is the second largest and fastest growing company among the top five companies of the country.
The company is dedicating a significant percentage of its resources to strengthening its technology including biotechnology, centered on Pharmaceuticals. Incepta currently manufactures and sells several bio-tech products in the local market. In order to expand its bio-tech business abroad Incepta has already established a state-of-the-art Human Vaccine production facility which will go into production soon.
Within six years of starting export operations, Incepta now sells its products in 40 countries. This has become possible due to an intellectual pool of some of the best minds in the country. Starting in 2006, Incepta already has registration of more than 300 products in different countries around the globe. Further negotiation with possible business partners and product registration is going on to further the presence of the company in many more countries.
In January 2008, the company received "Certificate of GMP compliance" from European Union which basically opened the door to the European market for Incepta.
UK MHRA, the regulatory authority of England has inspected the Zirabo plant of Incepta Pharmaceuticals Ltd in February 2011. Incepta received the GMP approval for its solid dosage form facility in July 2011 for its own formulated products allowing marketing in UK and other European countries.
In 2004 Incepta was inspected by UNICEF and UNDP and accepted as a potential supplier. In 2005 Incepta started supplying products to UNICEF locally in Bangladesh. Subsequently in 2010, Incepta was accepted by the global headquarters of UN agencies at Copenhagen, Denmark and became enlisted as global supplier to UNICEF, UNESCO, UNDP, UNRWA and UNFPA.
During the course of the last couple of years the company has received accreditation from many other countries of the world and currently holds the following GMP certificates from their respective Ministry of Health.
- UK MHRA GMP Certificate
- European Union GMP Certificate
- Turkey GMP Certificate
- Yemen GMP Certificate
- Kenya GMP Certificate
- Democratic Republic of Congo GMP Certificate
- Ethiopia GMP Certificate
- Uganda GMP Certificate
- Republic of Sudan
Incepta currently sells its product in many countries of Asia, Africa, Central America and has started to sell in Latin America and Europe. Incepta is taking special efforts to ensure presence in the rest of the globe. Currently the company is exploring distributorship, contract manufacturing, in licensing, technology partnership and many other forms of cooperation. Companies around the world can benefit from partnership with Incepta as the company offers a very large portfolio of generic products to choose from. Focus on ensuring high quality and cost effectiveness makes our portfolio more attractive to potential customers.